Brief: Pherecydes Pharma: First Patent Granted In Israel For Its Anti-Staphylococcus Aureus Phages

Pherecydes Pharma SA

29/11/2021 06:05

Nov 29 (Reuters) - Pherecydes Pharma SA  ALPHE.PA :
    * PHERECYDES PHARMA STRENGTHENS ITS INTELLECTUAL PROPERTY
WITH THE
FIRST PATENT GRANTED IN ISRAEL FOR ITS ANTI-STAPHYLOCOCCUS
AUREUS PHAGES AND PROVIDES AN UPDATE ON THE DEVELOPMENT SCHEDULE
FOR THIS FAMILY OF PHAGES
    * PATENT OBTAINED IN ISRAEL IS FIRST PATENT GRANTED FOR THIS
FAMILY OF PHAGES AND PROVIDES PROTECTION THROUGH TO END OF 2038
    * AAC AND PHAGODAIR APPLICATIONS ARE CURRENTLY BEING
REVIEWED AND
COMPANY EXPECTS TO RECEIVE RESPONSES BY EARLY 2022 AND Q1 OF
2022 RESPECTIVELY
    * INITIATION OF PHAGODAIR STUDY IS THEREFORE EXPECTED DURING
Q1 OF
2022 AND THAT OF PHAGOS AND PHAGOPIED STUDIES BEFORE END OF
FIRST HALF OF 2022

Source text for Eikon:  ID:nBw8FN719a 
Further company coverage:  ALPHE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))